Search JTA's historical archive dating back to 1923

News Brief

March 19, 2002
See Original Daily Bulletin From This Date

An Israeli-developed drug for the treatment of multiple sclerosis won approval for sale in the United States. REBIF, or Interferon Beta, developed at the Weizmann Institute of Science, delays relapses of the degenerative disease. The drug has been in use in Europe since 1996, and is available in more than 70 countries worldwide.

Recommended from JTA